Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02325466 · ClinicalTrials.gov registry record · Phase 3
Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 3
- Development phase
- 70
- Enrollment target
NCT02325466 is a Phase 3 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 70 participants.
The verdict
NCT02325466, a Phase 3 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 70 participants
- Enrollment target
Study Summary
The hypothesis being that both aspirin-ticagrelor and ticagrelor monotherapy will be superior to aspirin monotherapy in the reduction of whole blood viscosity at the end of each 4 week treatment period. Study participants will be randomized into 3 groups, and each group will receive each of 3 treatments in the cross-over study. At the end of each individual 4 week treatment period the investigators will determine whether there are differences in low and high shear rate dependent viscosity and investigate the effect of the treatment on peripheral arterial blood flow using pulse volume recordings, ankle brachial index and toe pressures. Subjects will be eligible if they have ankle-brachial index less than or equal to 0.85, or if a patient's blood vessels are calcified, patients will have toe-brachial index less than or equal to 0.6 performed using continuous-wave Doppler.
Interventions
- DRUG Aspirin
- DRUG Ticagrelor
- DRUG Ticagrelor Placebo
- DRUG Aspirin Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-05-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02325466
The ClinicalTrials.gov registry entry for NCT02325466 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Aspirin is the first listed.
NCT02325466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02325466 about?
NCT02325466 is a clinical study titled "Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes". The hypothesis being that both aspirin-ticagrelor and ticagrelor monotherapy will be superior to aspirin monotherapy in the reduction of whole blood viscosity at the end of each 4 week treatment period. Study participants will be randomized into 3 groups, and each group will receive each of 3 treatm...
What is the current status of trial NCT02325466?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 70 participants. The study started on 2015-04. Estimated completion is 2018-05-04.
What interventions are being tested in trial NCT02325466?
The interventions under investigation include: Aspirin (DRUG), Ticagrelor (DRUG), Ticagrelor Placebo (DRUG), Aspirin Placebo (DRUG).
Who is sponsoring clinical trial NCT02325466?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.